Literature DB >> 20423339

New drugs for neglected infectious diseases: Chagas' disease.

Fabiana S Machado1, Herbert B Tanowitz, Mauro M Teixeira.   

Abstract

Chagas' disease (CD) is caused by the protozoan Trypanosoma cruzi (Tc) and remains an important cause of morbidity and mortality. Most researchers in the field now agree that chronic low grade parasite persistence in tissue drives tissue damage and the autoimmune component of CD. Current therapy relies on two compounds: benznidazole and nifurtimox. Despite their long history in the treatment of CD, both compounds induce significant side-effects. In the current issue of the BJP, two contributions demonstrate that NO-donors are active, especially in combination with benznidazole, against Tc in vitro and in experimental models in vivo. The basic concept used by the authors to develop novel anti-Tc compounds relied on the demonstrated ability of nitric oxide to kill the parasite. There are several issues still to be resolved but the reported studies are a clear advance to the field and should be considered for further pre-clinical development.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20423339      PMCID: PMC2874848          DOI: 10.1111/j.1476-5381.2010.00662.x

Source DB:  PubMed          Journal:  Br J Pharmacol        ISSN: 0007-1188            Impact factor:   8.739


  16 in total

1.  Trypanosoma cruzi glycosomal glyceraldehyde-3-phosphate dehydrogenase: structure, catalytic mechanism and targeted inhibitor design.

Authors:  D H Souza; R C Garratt; A P Araújo; B G Guimarães; W D Jesus; P A Michels; V Hannaert; G Oliva
Journal:  FEBS Lett       Date:  1998-03-13       Impact factor: 4.124

2.  Trypanosoma cruzi-infected cardiomyocytes produce chemokines and cytokines that trigger potent nitric oxide-dependent trypanocidal activity.

Authors:  F S Machado; G A Martins; J C Aliberti; F L Mestriner; F Q Cunha; J S Silva
Journal:  Circulation       Date:  2000-12-12       Impact factor: 29.690

Review 3.  Glycolysis as a target for the design of new anti-trypanosome drugs.

Authors:  C L Verlinde; V Hannaert; C Blonski; M Willson; J J Périé; L A Fothergill-Gilmore; F R Opperdoes; M H Gelb; W G Hol; P A Michels
Journal:  Drug Resist Updat       Date:  2001-02       Impact factor: 18.500

Review 4.  The clinical immunology of human Chagas disease.

Authors:  Walderez O Dutra; Manoel Otávio C Rocha; Mauro M Teixeira
Journal:  Trends Parasitol       Date:  2005-10-19

5.  Nitric oxide donor trans-[RuCl([15]aneN)NO] as a possible therapeutic approach for Chagas' disease.

Authors:  Paulo M M Guedes; Fabiana S Oliveira; Fredy R S Gutierrez; Grace Kelly da Silva; Gerson Jhonatan Rodrigues; Lusiane Maria Bendhack; Douglas W Franco; Maria A Do Valle Matta; Dario S Zamboni; Roberto Santana da Silva; João Santana Silva
Journal:  Br J Pharmacol       Date:  2010-01-27       Impact factor: 8.739

6.  Infections in heart transplant recipients in Brazil: the challenge of Chagas' disease.

Authors:  Henrique L Godoy; Carla M Guerra; Ruy F Viegas; Rosiane Z Dinis; Joao N Branco; Vicente A Neto; Dirceu R Almeida
Journal:  J Heart Lung Transplant       Date:  2009-09-26       Impact factor: 10.247

7.  Susceptibility and natural resistance of Trypanosoma cruzi strains to drugs used clinically in Chagas disease.

Authors:  L S Filardi; Z Brener
Journal:  Trans R Soc Trop Med Hyg       Date:  1987       Impact factor: 2.184

8.  Structural basis for selective inhibition of trypanosomatid glyceraldehyde-3-phosphate dehydrogenase: molecular docking and 3D QSAR studies.

Authors:  Rafael V C Guido; Glaucius Oliva; Carlos A Montanari; Adriano D Andricopulo
Journal:  J Chem Inf Model       Date:  2008-02-28       Impact factor: 4.956

Review 9.  Perspectives on Trypanosoma cruzi-induced heart disease (Chagas disease).

Authors:  Herbert B Tanowitz; Fabiana S Machado; Linda A Jelicks; Jamshid Shirani; Antonio C Campos de Carvalho; David C Spray; Stephen M Factor; Louis V Kirchhoff; Louis M Weiss
Journal:  Prog Cardiovasc Dis       Date:  2009 May-Jun       Impact factor: 8.194

10.  CCR5 plays a critical role in the development of myocarditis and host protection in mice infected with Trypanosoma cruzi.

Authors:  Fabiana S Machado; Natalia S Koyama; Vanessa Carregaro; Beatriz R Ferreira; Cristiane M Milanezi; Mauro M Teixeira; Marcos A Rossi; João S Silva
Journal:  J Infect Dis       Date:  2005-01-13       Impact factor: 5.226

View more
  6 in total

1.  In Vitro and In Vivo Trypanosomicidal Action of Novel Arylimidamides against Trypanosoma cruzi.

Authors:  F H Guedes-da-Silva; D G J Batista; M B Meuser; K C Demarque; T O Fulco; J S Araújo; P B Da Silva; C F Da Silva; D A Patrick; S M Bakunova; S A Bakunov; R R Tidwell; G M Oliveira; C Britto; O C Moreira; M N C Soeiro
Journal:  Antimicrob Agents Chemother       Date:  2016-03-25       Impact factor: 5.191

Review 2.  Diagnosis and management of Chagas disease and cardiomyopathy.

Authors:  Antonio L Ribeiro; Maria P Nunes; Mauro M Teixeira; Manoel O C Rocha
Journal:  Nat Rev Cardiol       Date:  2012-07-31       Impact factor: 32.419

Review 3.  Developments in the management of Chagas cardiomyopathy.

Authors:  Herbert B Tanowitz; Fabiana S Machado; David C Spray; Joel M Friedman; Oren S Weiss; Jose N Lora; Jyothi Nagajyothi; Diego N Moraes; Nisha Jain Garg; Maria Carmo P Nunes; Antonio Luiz P Ribeiro
Journal:  Expert Rev Cardiovasc Ther       Date:  2015-10-23

4.  Challenges and perspectives of Chagas disease: a review.

Authors:  Paulo Câmara Marques Pereira; Elaine Cristina Navarro
Journal:  J Venom Anim Toxins Incl Trop Dis       Date:  2013-12-19

5.  Population pharmacokinetic study of benznidazole in pediatric Chagas disease suggests efficacy despite lower plasma concentrations than in adults.

Authors:  Jaime Altcheh; Guillermo Moscatelli; Guido Mastrantonio; Samanta Moroni; Norberto Giglio; Maria Elena Marson; Griselda Ballering; Margarita Bisio; Gideon Koren; Facundo García-Bournissen
Journal:  PLoS Negl Trop Dis       Date:  2014-05-22

6.  The metabogenic role of iron in chronic chagasic cardiac failure.

Authors:  Carla Paixão Miranda; Fernando Antônio Botoni; Maria do Carmo Pereira Nunes; Manoel Ótavio da Costa Rocha
Journal:  Mem Inst Oswaldo Cruz       Date:  2015-02-03       Impact factor: 2.743

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.